Evidence map›Paper›PMID 37740207›Full record

SynthesisAnnals of clinical microbiology and antimicrobials2023

"One Health" perspective on prevalence of co-existing extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae: a comprehensive systematic review and meta-analysis.

Tsepo Ramatla, Tshepo Mafokwane, Kgaugelo Lekota, Maropeng Monyama, George Khasapane, Naledi Serage, Jane Nkhebenyane, Carlos Bezuidenhout, Oriel Thekisoe

Open access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Annals of clinical microbiology and antimicrobials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed, 5 pooled it
7.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 5 syntheses or guidelines pooled it, 73 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Genomic Epidemiology of ESBL and Non-ESBL-ProducingAntibiotics (Basel, Switzerland) · 2026
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Tsepo RamatlaUnit for Environmental Sciences and Management, North-West University, Potchefstroom, 2520, South Africa. ra21205450@gmail.com.
Tshepo MafokwaneDepartment of Life and Consumer Sciences, University of South Africa, Florida, 1710, South Africa.
Kgaugelo LekotaUnit for Environmental Sciences and Management, North-West University, Potchefstroom, 2520, South Africa.
Maropeng MonyamaDepartment of Life and Consumer Sciences, University of South Africa, Florida, 1710, South Africa.
George KhasapaneDepartment of Life Sciences, Central University of Technology, Bloemfontein, 9300, South Africa.
Naledi SerageUnit for Environmental Sciences and Management, North-West University, Potchefstroom, 2520, South Africa.
Jane NkhebenyaneDepartment of Life Sciences, Central University of Technology, Bloemfontein, 9300, South Africa.
Carlos BezuidenhoutUnit for Environmental Sciences and Management, North-West University, Potchefstroom, 2520, South Africa.
Oriel ThekisoeUnit for Environmental Sciences and Management, North-West University, Potchefstroom, 2520, South Africa.
North-West University · ZACentral University of Technology · ZAUniversity of South Africa · ZA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe Escherichia coli (E. coli) and Klebsiella pneumoniae (K. pneumoniae) bacterial isolates that produce extended-spectrum β-lactamases (ESBLs) contribute to global life-threatening infections. This study conducted a systematic review and meta-analysis on the global prevalence of ESBLs in co-existing E. coli and K. pneumoniae isolated from humans, animals and the environment.

methodsThe systematic review protocol was registered in the International Prospective Register of Systematic Reviews (PROSPERO) [ID no: CRD42023394360]. This study was carried out following the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines. One hundred and twenty-six eligible studies published on co-existing antibiotic resistance in E. coli and K. pneumoniae between 1990 and 2022 were included.

resultsThe pooled prevalence of ESBL-producing E. coli and K. pneumoniae was 33.0% and 32.7% for humans, 33.5% and 19.4% for animals, 56.9% and 24.2% for environment, 26.8% and 6.7% for animals/environment, respectively. Furthermore, the three types of resistance genes that encode ESBLs, namely bla

conclusionsThe concept of "One-Health" surveillance is critical to tracking the source of antimicrobial resistance and preventing its spread. The emerging state and national surveillance systems should include bacteria containing ESBLs. A well-planned, -implemented, and -researched alternative treatment for antimicrobial drug resistance needs to be formulated.

Indexed as

Escherichia coliKlebsiella pneumoniaeAnimalsbeta-LactamasesHumansPrevalencebeta-LactamasesE. coliESBLGlobalK. pneumoniaemeta-analysisOne health

Identifiers

PMID37740207
PMCPMC10517531
OpenAlexW4386977118

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.